Drug Profile
Research programme: peripherally acting CB1 antagonists - Vernalis
Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Class
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 10 Sep 2008 Preclinical trials in Type-2 diabetes mellitus in United Kingdom (unspecified route)